Vascular endothelial growth factor (VEGF) and its receptor mediated signaling and angiogenesis play pivotal role in pathogenesis of GC; hence, various antiangiogenic agents (AAs) including both antibodies and tyrosine kinase inhibitors (TKIs) which target the angiogenic signaling pathways have been tested for GC treatment3–7, but only two AAs have been proved to improve the overall survival in GC or gastroesophageal junction (GEJ) cancer patients. This evidence concerns the gene VEGFA and gastric cancer.